We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

46 hedge funds and large institutions have $130M invested in Orchestra BioMed in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0% more funds holding

Funds holding: 46 → 46 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

1.93% less ownership

Funds ownership: 58.76% → 56.84% (-1.9%)

15% less capital invested

Capital invested by funds: $154M → $130M (-$23.7M)

Holders
46
Holders Change
–
Holders Change %
0%
% of All Funds
0.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
7
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Amitell Capital
Singapore
+$2.45M
2
IC
Ikarian Capital
Texas
+$2.44M
3
DKCM
Davidson Kempner Capital Management
New York
+$2.4M
4
AC
Athanor Capital
New York
+$726K
5
AAA
Affinity Asset Advisors
New York
+$304K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.57M
2
AIC
AWM Investment Company
New York
-$2.56M
3
GL
Governors Lane
New York
-$1.68M
4
KPF
K2 Principal Fund
Ontario, Canada
-$1.64M
5
PC
Periscope Capital
Ontario, Canada
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$9.55M – – –
CAM
2
Cormorant Asset Management
Massachusetts
$8.98M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$8.95M – – –
BlackRock
4
BlackRock
New York
$8.95M – – –
PI
5
Putnam Investments
Massachusetts
$8.42M – – –
Wellington Management Group
6
Wellington Management Group
Massachusetts
$7.17M -$2.57M -211,256 -25%
RCM
7
RA Capital Management
Massachusetts
$6.99M – – –
DKCM
8
Davidson Kempner Capital Management
New York
$6.96M +$2.4M +196,871 +46%
O
9
OrbiMed
New York
$5.59M – – –
AC
10
Amitell Capital
Singapore
$5.36M +$2.45M +201,221 +72%
PA
11
Perceptive Advisors
New York
$5.04M – – –
WP
12
Woodline Partners
California
$4.52M – – –
APM
13
Avidity Partners Management
Texas
$4.48M – – –
BC
14
Boxer Capital
California
$4.48M – – –
EC
15
EcoR1 Capital
California
$4.48M – – –
ACP
16
Acuta Capital Partners
California
$4.39M – – –
LGM
17
Logos Global Management
California
$3.36M – – –
Citadel Advisors
18
Citadel Advisors
Florida
$2.91M +$111K +9,090 +4%
SCM
19
Sio Capital Management
New York
$2.8M – – –
AAA
20
Affinity Asset Advisors
New York
$2.52M +$304K +25,000 +13%
IC
21
Ikarian Capital
Texas
$2.25M +$2.44M +200,000 New
BFM
22
Boothbay Fund Management
New York
$2.01M -$628K -51,561 -22%
PVI
23
Pura Vida Investments
New York
$1.23M +$116K +9,492 +9%
SFM
24
Sphera Funds Management
Israel
$1.12M – – –
MS
25
Maven Securities
Jersey
$1M – – –
1
2 3

OBIO Hedge Fund Activity: Q1 2021 in Review

46 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2021, worth a combined $130M — down 15% from $154M a quarter earlier.

Fund positioning in OBIO was balanced in Q1 2021: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Amitell Capital, adding an estimated $2.45M. The largest seller was Wellington Management Group, cutting an estimated $2.57M.

  • 46 institutional investors held Orchestra BioMed (OBIO) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $130M of Orchestra BioMed stock for Q1 2021, down 15% quarter-over-quarter.
  • 7 funds opened new Orchestra BioMed positions in Q1 2021 and 7 closed out, a net change of 0 holders.
  • The largest Orchestra BioMed buyer in Q1 2021 was Amitell Capital, an estimated $2.45M added.
  • The largest Orchestra BioMed seller in Q1 2021 was Wellington Management Group, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2021.